glp 1 and gip dual agonist GIPR/GLP-1R therapies for diabetes weight loss—chemistry, physiology, and clinical applications Major physiological roles of GLP-1

Support is part of medical care, not a sign of failure

A 26-week liraglutide study did not reduce amyloid levels or improve cognition, though it preserved how the brain uses glucose

Glycosuria contributes directly to improved glycemic control, while increased distal sodium delivery restores normal tubuloglomerular feedback, thereby lowering intraglomerular pressure, which is a key mechanism in slowing DKD progression [25,27]

Finan B, Mller TD, Clemmensen C, et al

In the phase 2b trial, however, the reductions in glycated hemoglobin and body weight in participants treated with NNC0090-2746 were similar to those in the group treated with liraglutide (76), and no phase 3 trial of NNC0090-2746 has been reported yet

Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)